

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF REVIEW AND APPROVAL BY CFDA
OF ESOMEPRAZOLE SODIUM FOR INJECTION

This is a voluntary announcement made by the board of directors (the “**Board**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”).

The Board is pleased to announce that, the Esomeprazole Sodium for injection (40mg) (handling number: CYHS1200078E) and the Esomeprazole Sodium for injection (20mg) (handling number: CYHS1300825E) (the “**Products**”) developed by the Group have been reviewed and approved by China Food and Drug Administration (the “**CFDA**”) for launching into market with the approval number of “Guo Yao Zhun Zi H20183071” and “Guo Yao Zhun Zi H20183072”, respectively.

Esomeprazole Sodium and its preparations are the first optical isomer proton pump inhibitor with clinical application, which are used clinically primarily for the treatment of gastric ulcer, duodenal ulcer, digestive esophagitis and gastritis. For patients with gastroesophageal reflux disease who cannot take oral medication, the Products possess unique advantages and can generate ideal efficacy.

Currently, the market demand for the Products is large while there are few manufacturers of the Products in the PRC market. The approvals for the Products will not only further enrich the product lines of the Group and drive the growth of the Group's results, but also provide patients with more options for pharmaceutical treatment and benefit the patients.

This announcement is a voluntary announcement made by the Company to keep the investors informed of the latest business development of the Group, and is not purported to contain any advertising or intention on use of any drugs, surgical equipment, therapeutic or oral products.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC

27 April 2018

As at the date of this announcement, the executive directors of the Company are Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. ZHU Qiaohong; the non-executive directors are Mr. TANG Xinfa and Mr. MO Kit; and the independent non-executive directors are Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming.